- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

S. 2620
U.S. Senate•In Senate Committee
Summary
S. 2620, the REMEDY Act, was introduced in the Senate on Jul 31, 2025 by Sen. Richard Durbin (D) with 1 co-sponsor. It was referred to Health, Education, Labor, And Pensions, and last saw action on Jul 31, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000).
Record
Text
S. 2620 has 1 co-sponsor.
sb2620/introduced-in-senate.txt119 S2620 IS: Reforming Evergreening and Manipulation that Extends Drug Years ActU.S. Senate2025-07-31text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.II119th CONGRESS1st SessionS. 2620IN THE SENATE OF THE UNITED STATESJuly 31, 2025Mr. Durbin (for himself and Mr. Cassidy ) introduced the following bill; which wasread twice and referred to the Committee onHealth, Education, Labor, and PensionsA BILLTo amend the Federal Food, Drug, and Cosmetic Act with respect to approvalof abbreviated new drug applications.1.Short titleThis Act may be cited as the Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act .2.Amendments to ANDA approval provisionsSection 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) is amended—(1)in subsection (c)(2) by adding at the end the following: With respect to a drug approved on or after the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , when a holder of an approved application first files information under this paragraph with respect to one or more patents described in subsection (b)(1)(A)(viii), the holder shall select one such patent with respect to which the owner or licensee may be eligible for the thirty-month period under paragraph (3)(C) or subsection (j)(5)(B)(iii), as applicable; for purposes of paragraphs (3)(C) and (3)(E)(ii) and subsections (j)(5)(B)(iii) and (j)(5)(F)(ii), such patent shall be referred to as the covered patent . The selection of such covered patent may not be changed or amended. ;(2)in subsection (c)(3)(C)—(A)in the matter preceding clause (i)—(i)by striking an action is brought for infringement and all that follows through the period at the end of the first sentence and inserting with respect to a drug approved under this subsection before the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of any patent that is the subject of the certification and for which information was submitted to the Secretary under paragraph (2) before the date on which the application (excluding an amendment or supplement to the application) was submitted, or, with respect to a drug approved under this subsection on or after the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of the covered patent (as described in paragraph (2)) that is the subject of the certification and for which information was submitted to the Secretary under paragraph (2) before the date on which the application (excluding an amendment or supplement to the application) was submitted. ; and(ii)by striking an action is brought before and inserting an action with respect to a patent or a covered patent, as applicable, is brought before ; and(B)in clause (i), by striking decides that the patent and inserting decides that the patent or the covered patent, as applicable ;(3)in the second sentence of subsection (c)(3)(E)(ii), by inserting with respect to any patent for which the requirements are met for the thirty-month period described in subparagraph (C) after action for patent infringement ;(4)in subsection (j)(5)(B)(iii)—(A)in the matter preceding subclause (I)—(i)by striking an action is brought for infringement and all that follows through the period at the end of the first sentence and inserting with respect to a drug approved under subsection (c) before the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of any patent that is the subject of the certification and for which information was submitted to the Secretary under subsection (c)(2) before the date on which the application (excluding an amendment or supplement to the application), which the Secretary later determines to be substantially complete, was submitted, or, with respect to a drug approved under subsection (c) on or after the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of the covered patent (as described in subsection (c)(2)) that is the subject of the certification and for which information was submitted to the Secretary under subsection (c)(2) before the date on which the application (excluding an amendment or supplement to the application), which the Secretary later determines to be substantially complete, was submitted. ; and(ii)by striking an action is brought before and inserting an action with respect to a patent or a covered patent, as applicable, is brought before ; and(B)in subclause (I), by striking decides that the patent and inserting decides that the patent or covered patent, as applicable, ; and(5)in the second sentence of subsection (j)(5)(F)(ii), by inserting with respect to any patent for which the requirements are met for the thirty-month period described in subparagraph (B)(iii), after action for patent infringement .
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-07-31
- Passed Senate
- Passed House
- Conference
- To President
- Became Law
CRS Summary
The summaries are the Congressional Research Service’s, one per stage. Read them in full.
Introduced in Senate Jul 31, 2025
sb2620/introduced-in-senate.mdShown Here:
Introduced in Senate (07/31/2025)
Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act
This bill limits the scope of a 30-month stay on approval of a generic drug by the Food and Drug Administration (FDA) while patent litigation involving the reference (brand-name) drug is ongoing.
Generally, entities seeking approval of a new drug must provide the FDA with information on patents claiming the drug or a method of use. Entities seeking approval of a generic drug must certify for each such patent on the reference drug that (1) the patent has expired or will expire before the generic is marketed, or (2) the patent is invalid or inapplicable to the generic drug. If a generic drug applicant certifies that a patent is invalid or inapplicable and a patent infringement suit is timely brought, the FDA is prohibited from approving the generic for 30 months (unless the patent litigation is resolved sooner). Under current law, this 30-month stay applies to patent litigation on any number of patents on a reference drug, provided the patent information was filed with the FDA before the generic application.
Under the bill, when an entity applies to the FDA for approval of a new drug, the entity must select only one patent to be eligible for the 30-month stay. This selection may not be changed or amended. After the bill’s enactment, only patent litigation related to the reference drug’s selected patent may trigger the 30-month stay on approval of a generic.
Sponsors
Sen. Richard Durbin (D) sponsors S. 2620, and 1 member has co-sponsored it from the day it was introduced.
Committees
S. 2620 went before 1 committee: Health, Education, Labor, and Pensions.

Actions
S. 2620 has taken 2 actions since Jul 31, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Jul 31, 2025 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)Health, Education, Labor, and Pensions Committee | ||
Jul 31, 2025 | — | Introduced in Senate |
Votes
S. 2620 has not gone to a roll call.
Titles
S. 2620 goes by 4 titles, 2 of them short titles.
- REMEDY Act — Display Title
- REMEDY Act — Short Title(s) as Introduced
- Reforming Evergreening and Manipulation that Extends Drug Years Act — Short Title(s) as Introduced
- A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications. — Official Title as Introduced
Lobbying
7 clients hired 7 firms and 93 registered lobbyists who named S. 2620 in 18 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Health Issues, Medicare/Medicaid, Budget/Appropriations, Copyright/Patent/Trademark, Pharmacy, Trade (domestic/foreign), Taxation/Internal Revenue Code, Insurance.
Clients
Who paid to be heard, by how many filings named the bill.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | — | District of Columbia | 1 | 4 | — |
| GSK (FKA GLAXOSMITHKLINE INC.) | — | District of Columbia | 1 | 4 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | — | District of Columbia | 1 | 4 | — |
| AARP | — | District of Columbia | 1 | 2 | — |
| KAISER FOUNDATION HEALTH PLAN INC | — | California | 1 | 2 | — |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | — | District of Columbia | 1 | 1 | $130K |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | no change | District of Columbia | 1 | 1 | — |
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 93.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| ADAM BECK | 1 | 1 | 4 |
| ANDREW SHINE | 1 | 1 | 4 |
| ANNA DUNBAR-HESTER | 1 | 1 | 4 |
| ANTHONY MITCHELL | 1 | 1 | 4 |
| ARON GRIFFIN | 1 | 1 | 4 |
| BART FORSYTH | 1 | 1 | 4 |
| BRENTON FISK | 1 | 1 | 4 |
| CATHERINE DOUGLAS | 1 | 1 | 4 |
| DAVID KORN | 1 | 1 | 4 |
| ELENORA CONNORS | 1 | 1 | 4 |
| FABIAN LUCERO | 1 | 1 | 4 |
| GARY BECK | 1 | 1 | 4 |
| HARMEET DHILLON | 1 | 1 | 4 |
| JAKE FREED | 1 | 1 | 4 |
| JEANETTE THORNTON | 1 | 1 | 4 |
| JOCELYN ULRICH | 1 | 1 | 4 |
| JOHN NAPPI | 1 | 1 | 4 |
| JUDITH HARON | 1 | 1 | 4 |
| KELLY GOLDBERG | 1 | 1 | 4 |
| LAUREN JEE | 1 | 1 | 4 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 first_quarter | $12.2M | 1st Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 third_quarter | $9M | 3rd Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 fourth_quarter | $8.4M | 4th Quarter - Report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 second_quarter | $7.4M | 2nd Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2026 first_quarter | $5.3M | 1st Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 third_quarter | $4.2M | 3rd Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2025 fourth_quarter | $4.1M | 4th Quarter - Report |
| AARP | AARP | 2026 first_quarter | $3.8M | 1st Quarter - Report |
| AARP | AARP | 2025 third_quarter | $3.8M | 3rd Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2026 second_quarter | $3M | 2nd Quarter - Report |
| KAISER FOUNDATION HEALTH PLAN INC | KAISER FOUNDATION HEALTH PLAN INC. | 2026 first_quarter | $3M | 1st Quarter - Report |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2025 third_quarter | $2.9M | 3rd Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2025 third_quarter | $1.7M | 3rd Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2026 first_quarter | $1.6M | 1st Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2026 second_quarter | $890K | 2nd Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2025 fourth_quarter | $810K | 4th Quarter - Report |
| KAISER FOUNDATION HEALTH PLAN INC | KAISER FOUNDATION HEALTH PLAN INC. | 2026 second_quarter | $530K | 2nd Quarter - Report |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 2025 third_quarter | $130K | 3rd Quarter - Report |
Classification
The Congressional Research Service files S. 2620 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; S. 2620’s is Health.
s2620/policy-areas.txtSource: congress.gov · legiscan.com